Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gastrointestinal stromal tumor (GIST)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-19 of 19 for your search:
Start Over
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
BGJ398 and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-140, NCI-2014-02117, NCT02257541
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: A6181196, NCI-2014-00205, 2011-002008-33, NCT01396148
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase: Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0784, NCI-2013-00030, NCT01738139
Sunitinib Malate Alternating with Regorafenib in Treating Patients with Gastrointestinal Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-149, NCI-2014-02033, ONC-2013-024, WI186553, NCT02164240
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 9605, NCI-2014-00626, 09-25-0099, 141525, 14-C-0150, P141525, NCT02192541
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 265, NCI-2015-00258, 9882, NCT02381561
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: DCC-2618-01-001, NCI-2015-01805, NCT02571036
Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BLU-285-1101, NCI-2015-02104, NCT02508532
Interferon Gamma-1b and Nivolumab in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU-084, NCI-2016-00138, NCT02614456
Start Over